Lorigerlimab

Multispecific antibody

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

Featured evidence outside this drug's tracked markets:NCT07071961 · Colorectal Cancer · Phase 2 · ungraded

Development in Metastatic Castration-Resistant Prostate Cancer stopped (2025-11-12) after a negative readout. Development continues in another indication. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (6)
Other / comorbidity
NCT07565155 · University of Miami
2027-01-01 – 2032-01-01 · Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
What this study did
NCT07071961 · M.D. Anderson Cancer Center
2026-02-11 – 2029-05-01 · Colorectal Cancer, Regorafenib, High Risk Patients
What this study did
NCT05475171 · M.D. Anderson Cancer Center
2022-12-13 – 2028-06-30 · Metastatic Cancer, Cervical Cancer
What this study did
NCT06730347 · MacroGenics
2025-05-01 – 2027-12 · Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer
What this study did
NCT07223567 · M.D. Anderson Cancer Center
2025-10-27 – 2026-01-22 · Rectal Cancer, Rectal Cancer Recurrent
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT07137390 · M.D. Anderson Cancer Center
2025-09-03 – 2026-01-22 · Colorectal Cancer
What this study did
Phase 1 (2)
Other / comorbidity
NCT05293496 · MacroGenics
2022-04-19 – 2025-08-26 · Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
What this study did
NCT03761017 · MacroGenics
2018-12-12 – 2025-01-27 · Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer, Advanced Cancer, Solid Tumor, Adult
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, 2 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lorigerlimab: this drugPhase 2Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary
Iparomlimab And Tuvonralimab
Phase 3(overall)
Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary
Volrustomig
Phase 3(overall)
Multispecific antibodyPD-1 x CTLA-4Partial signal
NCT05984277: Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). missed
Danvilostomig
Phase 2(overall)
Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary
AI-061
Phase 1(overall)
CombinationPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lorigerlimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
May 2027 (1)
Phase 2Colorectal Cancer, Regorafenib, High Risk PatientsRecruiting
Est. primary completion 2027-05-01 · NCT07071961 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma …Recruiting
Est. primary completion 2027-07 · NCT06730347 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Phase 2Metastatic Cancer, Cervical CancerRecruiting
Est. primary completion 2028-06-30 · NCT05475171 · CT.gov ↗
What to watch
2032 (1)
January 2032 (1)
Phase 2Pancreatic Adenocarcinoma, Homologous Recombination DeficiencyRecruiting
Est. primary completion 2032-01-01 · NCT07565155 · CT.gov ↗
What to watch

See the full readout calendar ↗